Benevolent AI (XAMS:BAI) Net Margin % : -1,308.09% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Benevolent AI Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Benevolent AI's Net Income for the six months ended in Dec. 2023 was €-30.88 Mil. Benevolent AI's Revenue for the six months ended in Dec. 2023 was €2.36 Mil. Therefore, Benevolent AI's net margin for the quarter that ended in Dec. 2023 was -1,308.09%.

The historical rank and industry rank for Benevolent AI's Net Margin % or its related term are showing as below:

XAMS:BAI' s Net Margin % Range Over the Past 10 Years
Min: -2327.67 Med: -953.62 Max: -393.79
Current: -863.21

XAMS:BAI's Net Margin % is ranked worse than
71.73% of 1026 companies
in the Biotechnology industry
Industry Median: -150.095 vs XAMS:BAI: -863.21

Benevolent AI Net Margin % Historical Data

The historical data trend for Benevolent AI's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benevolent AI Net Margin % Chart

Benevolent AI Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

Get a 7-Day Free Trial

-1,043.59

-801.57

-2,327.67

-1,552.36

-863.64

Benevolent AI Semi-Annual Data
	Dec18	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Margin %	Get a 7-Day Free Trial				-2,247.92	-2,916.77	-396.58	-693.05	-1,308.09

Competitive Comparison of Benevolent AI's Net Margin %

For the Biotechnology subindustry, Benevolent AI's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Benevolent AI's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benevolent AI's Net Margin % distribution charts can be found below:

* The bar in red indicates where Benevolent AI's Net Margin % falls into.

Benevolent AI Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Benevolent AI's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-73.496	/	8.51
	=	-863.64 %

Benevolent AI's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-30.884	/	2.361
	=	-1,308.09 %

Benevolent AI (XAMS:BAI) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Benevolent AI Net Margin % Related Terms

Thank you for viewing the detailed overview of Benevolent AI's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Benevolent AI (XAMS:BAI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benevolent AI (XAMS:BAI) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

BAIVF:USA 2XA:Germany

Address

4-8 Maple Street, London, GBR, W1T 5HD

Website

https://www.benevolent.com

Benevolent AI is a clinical-stage AI-enabled drug discovery company. It delivers novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains commercial collaborations with pharmaceutical companies.

Benevolent AI (XAMS:BAI) Headlines

No Headlines